Introduction
spite different chemical structures, most of the CCA used 21 today act via inhibition of the slow Ca -inward current 21 Calcium channel antagonists (CCA), potent vasodilators through L-type Ca -channels [3, 4] . Three main classes of widely used in the treatment of hypertension and angina CCA have been described: dihydropyridines (e.g. pectoris [1] , have also been proposed for the prevention of nifedipine), phenylalkylamines (e.g. verapamil) and bencardiac events after myocardial infarction (MI) [2] . De- zothiazepines (e.g. diltiazem). Whereas each of these drug classes has its own advantages, unwarranted effects, e.g., neurohormonal activation, AV-blockade, arrhythmias or day p.o.) with the start of treatment at different time points negative inotropic actions, often limit their use in cardiac before and after MI as indicated below (see Fig. 1 ): therapy. Dihydropyridine-type CCA are very potent peripheral vasodilators and can, therefore, produce reflex 1. sham (sham surgery, without treatment, n515) tachycardia [5] . In addition, negative inotropic effects have 2. placebo-treated MI (control MI, n515) been demonstrated in vitro and in vivo with CCA such as 3. 7d preMI (MI, start of treatment 1 week prior to nifedipine [6] and verapamil [7, 8] , which render these infarction, n513) compounds potentially dangerous in patients with a com-4. 3h postMI (MI, start of treatment 3 h after infarction, promised myocardial function [9, 10] . Diltiazem appears to n513) exert less negative inotropic effect than other CCA in 5. 24h postMI (MI, start of treatment 24 h after infarction, normal animals [11, 12] , but has been shown to impair left n514) ventricular function in dogs with volume overload-induced 6. 3d postMI (MI, start of treatment 3 days after infarccardiac hypertrophy and to produce severe bradycardia tion, n513) [13] . Furthermore, diltiazem has been shown to increase 7. 7d postMI (MI, start of treatment 7 days after infarcthe mortality in patients with clinical signs of heart failure tion, n513). following MI [14] . Possible explanations of these adverse effects of CCA are their depressant effects on cardiac After one week in single cages, rats in group 1 underfunction through direct negative inotropic and dromotropic went a sham operation. In the remainder of rats, MI was actions on the myocardium and neurohormonal activation induced by permanent ligation of the left coronary artery. which can produce cellular damage [15, 16] .
Food and water intake as well as body weight (BW) were Mibefradil is a novel tetrazolium CCA featuring an measured every second day before induction of MI, every 21 inhibition of both, the L-and T-type Ca -channels, with a day in the first week after MI, every second day in the 21 higher selectivity for T-type Ca -channels with respect to second and third week and every third day in the fourth, 21 L-type Ca -channels [17] . Mibefradil has preferential fifth and sixth week after MI. coronary vasodilative effects and, in animal experiments, Treatment was given once daily via gastric gavage and this compound was shown to increase coronary blood flow was continued for 6 weeks after MI. Mibefradil was during ischemia induced by lowering coronary perfusion dissolved in water at a concentration of 10 mg / ml. Six pressure in dogs [18] . Pharmacological and clinical eviweeks after MI or sham operation, chronic arterial and dence has been presented that mibefradil does not exert venous catheters as well as a catheter in the left ventricle negative inotropic actions in isolated rat hearts [19] and in were implanted to measure haemodynamic data. Haemopatients with stable angina pectoris [20] . Thus, mibefradil dynamic studies were performed 24 h later in conscious might be a safer drug than other CCA in patients with MI, animals. At the end of the experiments, the rats were especially when left ventricular dysfunction occurs.
sacrificed, and the hearts were excised and fixed with The aim of the present study was to characterize the paraformaldehyde for morphological studies. effects of a long-term treatment with mibefradil on cardiac function and morphology in a rat model of chronic heart 2.1. Surgical procedures failure after MI. Mibefradil treatment was started at different time points prior to and after permanent coronary MI was induced by permanent ligation of the left ligation to establish the optimal time point for commencing coronary artery using a modified version of the technique therapy.
described by Johns and Olson [21] . Briefly, rats were anaesthetized with ether to cannulate the tail vein for intravenous injections of methohexital-sodium (10 mg / 2. Methods kg). The chest of the animals was shaved and disinfected. Rats were intubated and artificially ventilated with room Male normotensive Wistar rats (Charles River Viga, air (50 hubs / min, 200 mmH O, 1.5 ml / hub). The electro-2 Sulzfeld, Germany) initially weighing 230-270 g were cardiogram (ECG) was monitored continuously during used in the study. All experiments were performed in surgery. A left thoracotomy was started by incising the accordance with the German law on animal protection as skin 2 cm parallel to the third and fourth rib. The pectoral released in its new version in 1993. The animals were muscles were dislocated to expose the ribs and the incision housed individually at controlled temperature and humidity was done at the fourth intercostal space to insert a ribunder a 12-h-light / dark-cycle. Rats had free access to a spreading chest retractor. After anterior pericardectomy, standard diet (Altromin®, Altromin International GmbH the heart was exposed. The left coronary artery was then u.Co.Kg., PF 1120, 32770 Lage-Lippe, Germany) and to ligated intrathoracally using sterile 6-0 suture material drinking water. They were divided randomly into seven (Ethibond, Ethicon, Norderstedt, Germany) under a groups: sham operation, control MI and placebo treatment stereomicroscope. Successful ligation of the coronary and groups subjected to mibefradil treatment (10 mg / kg / artery was verified by the occurrence of arrhythmias in the ECG and, visually, by observing the colour changes of the was then tunnelled under the skin and anchored at the ischemic area. In rats that underwent sham surgery, posterior neck region. ligation was placed beside the coronary artery. The thoracic cavity was closed during respiration hold. At the 2.3. Haemodynamic measurements end of the operation procedure, analgesia was induced by a subcutaneous injection of buprenorphine-HCl (0.2 mg / kg).
In preliminary experiments, the femoral artery was cannulated to measure arterial blood pressure and heart rate (HR) during surgery and during the 48 h time interval 2.2. Arterial, venous and left ventricular catheters after induction of MI or sham operation. Six weeks after induction of MI haemodynamic meaAt the end of the study, 6 weeks after MI, the animals surements were performed 24 h after the implantation of were anaesthetized with ether. Anaesthesia was continued the catheters in conscious rats as described previously [23] . by intravenous injection of methohexital-sodium (10 mg / The femoral artery-and left ventricular-catheter were kg). Femoral arterial and venous catheters were chronically connected to the pressure transducers (DTX / Plus, Specimplanted using a procedure described elsewhere [22] .
tramed, Oxnard, CA, USA). Mean arterial blood pressure Briefly, polypropylene tubes (Portex, London, UK) were (MAP), HR and left ventricular pressure (LVP) were inserted into the right femoral artery and vein and exteriorobtained using two pressure processors (Gould, Valley ized at the nape of the neck. The left ventricle was then View, OH, USA). The output signals were recorded on a cannulated using a specially constructed pig-tail catheter pen recorder (Gould Series 2000, Gould) and analysed by consisting of a PP10 tube 60 mm in length welded to a 350 a computer-based system MEGA [24] at a rate of 800 Hz. mm length of PP50 tube [23] . The pig-tail at the end of the The computer program calculated the left ventricular PP10 portion was inserted into the right carotid artery and enddiastolic pressure (LVEDP) and the maximum positive advanced into the left ventricle via the ascending aorta. change in the left ventricular pressure signal (dP/dt ) max During cannulation, the catheter was connected to a (1000 mmHg / s). The last parameter was considered as a transducer and blood pressure monitor to verify the marker of the myocardial contractility. Since ECG was not position of the tip of the catheter. The left ventricle was recorded in this part of the study, LVEDP was measured at considered to be reached when the pulse pressure had a the point where the slope of the ventricular pressure signal typical left ventricular configuration. The PP50 portion changed from the slowly to the rapidly increasing portion [25] . This point has been shown to be closely linked to the transsections, MI was clearly detectable with scar tissue R-wave of the ECG and to represent LVEDP in rats [23] .
showing a green colour and the remaining myocardium a Rats were given time to get acquainted with the recordred colour. For morphometric measurement of IS and the ing procedures for 30 min before baseline measurements of extent of ventricular dilatation, a computerised surface MAP, HR and LVP were recorded. The animals then determination method which employed onscreen visualisareceived an intravenous infusion of the a1-adrenoceptor tion of the cardiac transsections (Quantimet 570 moragonist, methoxamine (2.0 mg / kg / h) to increase cardiac phometer including morphometry software, Leica, Camafterload. The rate of infusion was increased steadily until bridge Instruments, Cambridge, UK, connected to a video MAP was elevated by about 20 mmHg. An infusion rate of camera) was used. Endocardial and epicardial circumfer-0.5-1.0 mg / h was usually necessary to attain the desired ence of the whole left ventricle and of the scar tissue were constant pressure response. This infusion rate was mainoutlined by the computer. The borderline between the tained, and a second recording was obtained. LVEDP and infarcted area and the remaining myocardial muscle was myocardial contractility were calculated offline from the exactly marked with a pointer. Thereafter, the IS was LVP signal using the MEGA program. MAP, HR, LVEDP calculated by the system as the percentage of the LVC and dP/dt under basal conditions and during increased [27, 28] . 
D G
total endocardial circumference 2 were excluded from the protocol since substantial haemodynamic changes are only apparent in animals with an
In addition, the average ST was determined as the septal infarction larger than 21% [26] .
area enclosed by two lines originating from the center of gravity of the left ventricular endocardial circumference, 2.4. Tissue processing which connected the two origins of right ventricular free wall, divided by the average of right and left ventricular After haemodynamic measurements, rats were sacrificed surface length [29] . The determination of IT was measured and the hearts were stored in 4% phosphate buffered in the same way as ST. Total IL, NL, mean LVC and LVD formalin in 0.15 M NaCl for morphological examinations.
of the transsection were also calculated by the computer Macroscopically, MI was found to be transmural in all according to the formulae below: infarcted rats. After removal of the atria and large vessels, area of the septum the ventricles were cut in a standardized fashion number of rats in each group was too low to yield statistically valid data.
Drugs
Mibefradil was kindly provided by Hoffmann-La Roche (Grenzach-Wyhlen, Germany). In preliminary experiments, the dosage of 10 mg / kg / day mibefradil chronically administered via gastric gavage did not significantly influence MAP in infarcted or sham-operated animals. In these experiments, a 24 h blood pressure profile was measured in conscious rats beginning immediately after p.o. application of mibefradil (5-15 mg / kg / day) to determine a dose which did not affect cardiac function under control conditions. 
Statistical analysis
Indicated are animals subjected to control MI animals (placebo, black column) and mibefradil-treated animals (10 mg / kg / day p.o.) started at Statistical evaluation of obtained haemodynamic and different time points before and after induction of MI (striped columns, 7d preMI, 3h postMI, 24h postMI, 3d postMI, 7d postMI). Data represent morphometric data was performed using one-way analysis
of variance with repeated measures. Means shown to be different between individual groups were compared using the posthoc Student's t-test and were considered significant group compared to the sham-operated group. Cardiac at p,0.05. Data were expressed as mean6standard error weights of 7d preMI, 3h postMI, 24h postMI and 3d of the mean (S.E.M.).
postMI mibefradil-treated groups tended to decrease when compared to the placebo-treated MI group but this difference was not statistically significant (Table 1) .
Results
The IS is shown in Fig. 2 and the IL in Table 1 . The IS determined as percentage of the LVC was 3962% and the 3.1. Morphology IL was 10.260.7 mm in the placebo-treated MI group. Early treatment with mibefradil (7d preMI and 3h postMI) After induction of MI, food and water intake was reduced IS and IL as compared to placebo-treated MI reduced in all animals followed by a decrease of BW (data animals. No significant reductions in IS and IL were seen not shown). Seven days after MI the food and water intake when mibefradil treatment was begun 24 h, 3 days and 7 was normalized and was not different from sham-operated days after induction of MI. IT was not different between animals any more. During the following weeks of the placebo-treated MI and mibefradil-treated animals (Table experiment, no differences in food and water intake as well 1). as BW were observed between the groups.
The LVD and LVC were used to determine left ventricuCardiac weight was examined by determining the ratio lar expansion. LVD (Fig. 3) and LVC (Table 1) were of THW to BW. THW/ BW was increased in the placeboincreased in the placebo-treated MI group when compared treated MI group and in the 7d postMI mibefradil-treated to the sham group. Both parameters, were significantly reduced by mibefradil treatment when begun 7 days preMI the placebo-treated MI group and 7d preMI and 3h postMI and tended to decrease when mibefradil treatment was mibefradil-treated groups was increased compared to the commenced 3 h postMI as compared to the placebo-treated sham group. Animals of the 7d preMI mibefradil-treated MI group. No differences in LVD and LVC with respect to group showed a tendency for reduction in HR compared to the placebo-treated MI group were detected when mibefthe placebo-treated MI group (Fig. 5B ). radil treatment was commenced 24 h, 3 days and 7 days Six weeks after surgery, a decrease of MAP (Table 2) , postMI.
increase of LVEDP and decrease of cardiac contractility at NL was increased in 7d preMI and 3h postMI mibefbaseline (Fig. 6A, Fig. 7A ) and after methoxamine stimuradil-treated groups as compared to the placebo-treated MI lation (Fig. 6B, Fig. 7B ) were observed in the placebogroup. No differences in NL compared to the placebotreated, infarcted animals when compared to sham-opertreated MI group were detected when mibefradil treatment ated animals. To test cardiac function after increased was commenced between 24 h postMI and 7 days postMI afterload, a methoxamine infusion was initiated and steadi-( Table 1) . ly increased until MAP was elevated in all groups by 20 ST was reduced in the placebo-treated MI group as mmHg as compared to baseline. Animals of the placebocompared to the sham group (Fig. 4) . ST was increased in treated MI group had to be infused with higher doses of all mibefradil-treated groups as compared to the placebomethoxamine to increase blood pressure by 20 mmHg as treated MI group and was, in addition, increased in 7d compared to sham-operated animals ( Table 2 ). In contrast, preMI and 3h postMI mibefradil-treated groups as comthe consumption of methoxamine to increase blood prespared to the sham group. Left ventricle noninfarcted area sure by 20 mmHg was reduced in the mibefradil-treated (NL3ST) was increased in 7d preMI, 3h postMI and 24h groups when treatment was begun 7 days preMI or 3 h postMI mibefradil-treated groups compared to the placebopostMI (Table 2) . treated MI group (Table 1) .
Six weeks after induction of MI, MAP was decreased in all infarcted groups as compared to the sham-operated 3.2. Haemodynamics group. The mibefradil-treated animals in the 7d preMI, 3h postMI and 24h postMI treated groups showed higher MAP, measured in separate groups (n56-8) during MAP values at baseline compared to the placebo-treated surgery and during the 48 h time interval after operation, MI group (Table 2) . was reduced in the placebo-treated MI group and in HR at week 6 after MI / sham surgery did not differ mibefradil-treated groups (7d preMI and 3h postMI) significantly among the seven groups at baseline or after immediately after MI and during the following 48 h period methoxamine infusion (Table 2) . as compared to sham-operated animals. No significant Placebo-treated MI rats had higher LVEDPs at baseline differences were seen between the placebo-treated MI and during increased afterload than those that underwent group and the mibefradil-treated groups (Fig. 5A) . HR of sham surgery. In the mibefradil-treated groups 7d preMI, 3h postMI, 24h postMI and 3d postMI, LVEDP was reduced at baseline as compared to the placebo-treated MI group. LVEDP of all mibefradil-treated groups was reduced after methoxamine stimulation. LVEDP of mibefradil-treated animals was increased in 3h postMI, 24h postMI, 3d postMI and 7d postMI groups at baseline and after methoxamine stimulation as compared to the sham group ( Fig. 6A and B) . In contrast to the other mibefradiltreated groups, LVEDP in the 7d preMI mibefradil-treated group was not significantly increased at baseline and after methoxamine stimulation as compared to the sham-operated group (Fig. 6A and B) . Myocardial contractility (dP/dt ) at baseline and max during increased afterload was reduced in placebo-treated MI rats as compared to sham-operated animals. dP/dt max was increased in mibefradil-treated groups, 7d preMI and 3h postMI at baseline and after methoxamine stimulation as compared to placebo-treated MI rats. dP/dt was max reduced in mibefradil-treated groups 3h postMI, 24h postMI, 3d postMI and 7d postMI at baseline and after methoxamine stimulation as compared to sham-operated animals. Cardiac contractility did not differ from shamoperated animals at baseline and after methoxamine stimulation when mibefradil treatment was initiated 7 days prior to induction of MI ( Fig. 7A and B) .
Mortality
In all infarcted groups, the highest mortality (47-51%) occurred within 24 h after surgery. One out of 15 rats died group534; 7d postMI mibefradil-treated group539.4. formed to determine the degree of alterations of the 4. Discussion morphological parameters (remodeling) of the left ventricle after MI. The purpose of this investigation was to examine the The experimental model used in the present experiments effects of chronic treatment with the CCA, mibefradil, on features pronounced heart failure 6 weeks after the induchaemodynamic and morphological parameters following tion of MI. At this time point, remodeling usually has MI. Six weeks after permanent ligation of the left anterior taken place and stable haemodynamic conditions can be coronary artery, ventricular performance was assessed at expected [30] . Our results show an increased LVEDP and baseline and after increased afterload induced by methoxan impaired myocardial contractility (dP/dt ) in animals max amine infusion. Morphometric examinations were perof the placebo-treated MI group. The changes of both parameters were accompanied by a reduction of MAP. induced sympathetic activation and reflex tachycardia Eccentric cardiac hypertrophy was present, which was [18, 34, 42] . evidenced by a left ventricle dilatation and increase in Coronary occlusion may induce hypotension, which cardiac weight without an increase in ST thickness. Results results in baroreceptor activation and subsequent systemic of several studies demonstrated that this dilatative hyreflex vasoconstriction thus worsening the imbalance bepertrophy is accompanied by cardiac fibrosis as evidenced tween myocardial oxygen demand and supply [43] [44] [45] . by the accumulation of collagen and an elevated stiffness Moreover, after coronary occlusion, lactate, the end prodof the infarcted and noninfarcted hypertrophied areas uct of glycolysis, accumulates in the tissue as a conse- [31, 32] . Compared to placebo-treated MI rats, LVEDP at quence of the anaerobic metabolism in the myocytes. In baseline was significantly lowered in mibefradil-pretreated addition, myocardial injury during ischemia or after infarcanimals and when treatment was started within 3 days after tion is thought to be associated with a cellular accumula-MI at baseline, and also in all mibefradil-treated groups tion of calcium [46] . It is possible that, in our experiments, during increased afterload. The observed effects of mibefearly-onset of mibefradil treatment protected the heart by radil on LVEDP are partly attributed to a reduction in increasing oxygen supply due to an improved perfusion of afterload. However, preload plays also an important role in the myocardium in the noninfarcted area and, especially, in influencing LVEDP and might contribute to the reduction the marginal zone of the infarcted area (''area at risk''). of cardiac hypertrophy [60] . The effect on LVEDP was
The dilatative action of mibefradil on coronary arteries is accompanied by an increased dP/dt under basal conthought to be mediated by a direct inhibition of vascular max 21 ditions and during increased afterload in animals in which smooth muscle contraction via L-and / or T-type Catreatment was started 7 days prior to and 3 h after coronary channels as well as an endothelium-dependent relaxation artery ligation. This finding indicates an improved myocarby increasing the release of endothelium-derived relaxing dial contractility in animals with early-onset treatment.
factor [66] . A marked vasodilatory action of mibefradil on Indeed, LVEDP and dP/dt of 7 day pretreated rats were the coronary arteries has previously been demonstrated in max not significantly different from sham-operated animals. isolated, perfused guinea pig hearts showing that mibefThe lack of a negative inotropic effect of mibefradil in radil produced a larger increase in coronary blood flow our experiments is in agreement with results of other and, at the same time, a smaller decrease in left ventricular studies, which have shown that mibefradil had no adverse pressure than other CCA [36] . Furthermore, in contrast to effect on contractile function in a rat model of heart mibefradil, the doses needed to double coronary blood failure, whereas verapamil depressed cardiac function in flow of other, nondihydropyridine CCA such as verapamil this model [33, 34] , and that mibefradil exerted less negaand diltiazem, were very close to those producing firsttive inotropic actions than diltiazem [35] . Another study degree AV-block which limited the therapeutic use of these has shown that mibefradil had a tenfold lower potency than drugs [47, 48] . Mibefradil treatment might thus have reverapamil for reducing myocardial contractility [36] .
sulted in a reduction in the rate of the ischemic anaerobic Negative inotropy has also been demonstrated in vitro and metabolism of the myocardium after MI reducing the in vivo in normal hearts with CCA such as nifedipine and calcium overload of the myocytes. The latter effect enverapamil [6, 7] . Diltiazem appears to afford less cargenders a lowering of the energy demand for the maintediosuppression than other CCA in normal animals nance of the calcium homeostasis thereby improving the [6, 11, 12] but impaired left ventricular function in conenergy state of the myocytes. In sustained ischemia, a scious dogs with volume overload-induced cardiac hyreduction of energy metabolism has been shown to reduce pertrophy [13] and in the isolated hypertrophied failing cellular damage [49] . heart [37] at a dose which did not affect cardiac function in An IS limiting property of mibefradil has already been the control state.
shown in the reperfused infarction model of dogs [50] . In Some CCA of the dihydropyridine type stimulate the our experiments, when mibefradil treatment was comsympathetic nervous system which is reflected by an menced 7 days prior to and 3 h after induction of MI, IS elevation of HR as well as of circulating adrenaline-and and IL were significantly reduced accompanied by a noradrenaline levels [38] [39] [40] . A tachycardic response to significant increase of the NL in these two groups. In mibefradil was not observed in the present study, rather a addition, LVD and LVC were reduced when mibefradil tendency to a decreased HR which was, however, statistitreatment was started 7 days prior to and 3 h after coronary cally not significant. In addition, mibefradil pretreated MI artery ligation. These data indicate that myocardial strucanimals showed a slight decrease in HR during the acute ture postMI is best preserved when mibefradil treatment phase after operation and during the 48 h time interval has already been commenced before or is installed within 3 after induction of MI. These findings could be partly h after the acute event. explained by the fact that cardiac T-channels, preferenAn interesting finding of this study is that in all tially blocked by mibefradil, are located primarily in the mibefradil-treated groups except the 7d postMI group, sinus node [41] . Our data are in agreement with results of heart weight was not increased over sham-operated aniother studies showing that mibefradil prevented ischemiamals. If an increase of total cardiac weight can be taken as a reflection of cardiac remodeling, these findings suggest mibefradil pretreatment prevented an increase of intracelluthat remodeling was not entirely dependent on the effects lar calcium concentration after MI in the rat papillar of treatment on IS but seemed to have an independent muscle (Sandmann et al., in preparation). The inhibition of drug-related component. Evidence has been presented that calcium entry into ischemic myocytes could stem from the 21 T-type Ca -channels can promote cell growth and proliffact that mibefradil blocks calcium entry more potently in 21 eration [51, 52] . In addition, T-type Ca -channels are depolarised cells, because ischemic myocardial tissue is overexpressed in failing hearts [53] but not in healthy adult depolarised [67] . rat hearts [64, 65] . In support of these findings, in myocytes
The present study demonstrated that mibefradil treat- 21 of cardiomyopathic hamsters the density of T-type Cament starting either 7 days prior to or within 3 days postMI channel currents was increased, and abnormal channel improved morphological and haemodynamic parameters activity and inactivation kinetics were observed, whereas after 6 weeks. In these four groups, fewer animals had to 21 the density of L-type Ca -channel currents and activity be operated in order to obtain adequate numbers of animals were constant [61] . Thus, the cardioprotective effects of surviving the protocol as compared to placebo-treated or mibefradil might be more pronounced in the failing heart 7d postMI mibefradil-treated groups. This suggests that which is related to an increased expression of T-type mibefradil treatment may reduce mortality and prolong life 21 Ca -channels. An antiproliferative effect of mibefradil in in rats when initiated within the first days after MI. This rat arteries has already been reported [54] . Based on these hypothesis is supported by experiments performed over a 9 findings, it is tempting to speculate that mibefradil, through month period in rats with chronic heart failure demon- 21 its effect on T-type Ca -channels, reduced postMI cardiac strating that mibefradil improved survival to the same hypertrophy to a greater extent than what could have been extent as the angiotensin-conversions-enzyme (ACE) inexpected by the reduction of IS alone. The higher number hibitor cilazapril [63] . 21 and activity of T-type Ca -channels under hypertrophic In conclusion, our data demonstrate that early-onset 21 conditions suggests an influence of this channel type on treatment with the preferentially T-type Ca -channel 21 intracellular Ca -levels. A contribution of this channel blocking agent, mibefradil, improves cardiac performance type in remodeling processes in heart failure could explain and reduces IS as well as cardiac remodeling in chronic the antihypertrophic and antiproliferative effects of mibefheart failure postMI. Cardioprotection was greatest when radil due to its T-channel blocking action. The effects of treatment was begun before or within 3 h after the acute 21 21 mibefradil are not only related to T-type Ca -channels ischemic event. Several features of selective T-type Cabecause mibefradil has recently been shown to inhibit channel blockade may have contributed to mibefradil's 2 calcium-activated Cl -channels in endothelial cells folbeneficial action on the heart including the lack of symlowed by a concomitant hyperpolarisation indicating a patho-activation and of negative inotropy as well as an 21 modulation of the Ca -signalling mechanism [62] . This inhibition of growth effects mediated through this parfact might contribute to the complex cardiovascular actions ticular calcium channel. Whether or not an improved of the compound.
coronary perfusion in the marginal zone of the infarct The specificity of the beneficial effects of CCA in the and / or a prevention of ischemia-induced cellular calcium ischemic heart is still a matter of debate. According to a overload contribute to the effects of mibefradil needs to be widely discussed hypothesis, increased intracellular calfurther investigated. cium after ischemia is a major mediator of structural and functional deterioration of the myocardium. Previous studies have demonstrated that cardiac necrosis can be
